期刊文献+

闭式胸腔引流联合洛铂治疗恶性胸腔积液的临床观察 被引量:7

原文传递
导出
摘要 目的探讨闭式肠腔引流联合洛铂胸腔内灌注化疗治疗恶性胸腔积液的疗效及药物毒副作用。方法 30例通过胸腔细胞学或病理学确诊的恶性胸腔积液患者,肺癌17例,乳腺癌10例,恶性间皮瘤2例,胰腺癌1例。采用留置导管胸腔闭式引流,待引流结束后将洛铂50mg溶于5%葡萄糖注射液50ml中经导管注入胸腔,2周内给药1~3次。观察毒副作用,化疗结束后4周判定疗效。结果 30例患者共胸腔内灌注化疗49次,每例1~3次。治疗1次者14例,2次者13例,3次者3例。治疗后评价完全缓解10例(33.3%),部分缓解16例(53.3%),未缓解4例(13.3%),总有效率86.7%。毒副作用小,均为Ⅰ~Ⅱ度。结论对原发肿瘤来自不同系统的恶性胸腔积液,在充分胸腔引流的基础上采用洛铂胸腔灌注化疗治疗,疗效肯定,毒副反应轻微。
出处 《中国临床研究》 CAS 2013年第5期452-453,共2页 Chinese Journal of Clinical Research
  • 相关文献

参考文献12

  • 1Olden AM, Holloway R. Treatment of malignant pleural effusion : PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis [ J]. J Palliat Med,2010,13 ( 1 ) :59 - 65.
  • 2杨柳青,秦叔逵.第3代铂类药物洛铂的研究新进展[J].临床肿瘤学杂志,2009,14(12):1134-1139. 被引量:108
  • 3Rodrignez-Panadero F, Romero-Romero B. Management of malignant pleural effusions [ J]. Curt Opin Pulm Med, 2011,17 (4) : 269 - 273.
  • 4Ismail-Khan R, Robinson LA, Williams CC Jr, et al. Malignant pleu- ral mesothelioma : a comprehensive review [ J ]. Cancer Control, 2006,13 (4) :255 - 263.
  • 5Tamsma JT, Keizer H J, Meinders AE. Pathogenesis of malignant as- cites:Starling's law of capillary hemodynamics revisited [ J ]. Ann Oncol,2001,12(10) : 1353 - 1357.
  • 6Grove CS, Lee YC. Vascular endothelial growth factor: the key medi- ator in pleural effusion formation [ J ]. C urr Opin Pulm Med ,2002,8 (4) :294 -301.
  • 7Kaifi JT, Toth JW, Gusani N J, et al. Multidisciplinary management of malignant pleural effusion [ J ]. J Surg Oncol, 2012,105 ( 7 ) : 731 -738.
  • 8Swiderek J, Morcos S, Donthireddy V, et al. Prospective study to de- termine the volume of pleural fluid required to diagnose malignancy [J]. Chest,2010,137 ( 1 ) :68 -73.
  • 9Gordon CE, Feller-Kopman D, Balk EM, et al. Pneumothorax follow- ing thoracentesis : a systematic review and meta-analysis [ J ]. Arch Intern Med,2010,170 (4) :332 - 339.
  • 10Abouzgheib W, Bartter T, Dagher H, et al. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion[ J]. Chest,2009,135 (4) :999 - 1001.

二级参考文献38

共引文献112

同被引文献49

  • 1谢文琴,金少华,贾尚春,谢建嵘,徐粒子,李建.安徽省1996~2005年恶性肿瘤死亡率分析[J].安徽预防医学杂志,2007,13(2):96-98. 被引量:7
  • 2Jakupec M A, Galanski M, Keppler B K. Turnout-inhibiting platinum complexes state of the art and future perspectives [J]. Rev Physiol Biochem Pharmacol, 2003, 146: 1-53.
  • 3Monneret C. Platinum anticancer drugs. From serendipity to rational design [J]. Ann Pharm Fr. 2011, 69(6): 286-295.
  • 4贺敏.中心静脉导管闭式引流联合顺铂或洛铂心包腔灌注治疗恶性心包积液的疗效比较【C]//第13届全国肺癌学术大会论文汇编.2013:211.
  • 5黎鹏,王树堂,林丽珠.重组人p53腺病毒注射液联合洛铂冶疗恶性胸腔积液[J].医药前沿,2013,(15):165.
  • 6张丽,张恒,韩斌,等.洛铂和五昧子多糖胸腔内注射在肺癌伴胸腔积液治疗中的应用[J】.中国保健营养,2012,13:484-485.
  • 7Uzbeck MH, Almeida FA, Sarkiss MG, et al. Management of" malig- nant pleural effusions [ J ] Adv Ther, 2010, 27 (6) : 334-347.
  • 8Neragi-Miandoab S. Malignant pleural effusion, current andewlving approaches for its diagnosis and management [ J ]. Lung Cancer, 2006, 54 ( 1 ) : 1-9.
  • 9Kaifi JT, Toth JW, Gusani NJ, et al. Multidisciplinary management of malignant pleural effusion [ J ]. J Surg Oncol, 2012, 105 (7) : 731- 738.
  • 10Wang X, Zhang L. Physieochenfieal properties and antitumor activi- ties for sulfated derivatives of lentinan [ J]. Carbohydr Res, 2009, 344(16) : 2209-2216.

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部